Biclar Junior

Biclar Junior may be available in the countries listed below.

Ingredient matches for Biclar Junior

Clarithromycin

Clarithromycin is reported as an ingredient of Biclar Junior in the following countries:

• Belgium

International Drug Name Search

Rilonacept

Pronunciation: ril-ON-a-sept
Generic Name: Rilonacept
Brand Name: Arcalyst

Rilonacept is used for:

Treating certain types of genetic syndromes (cryopyrin-associated periodic syndromes [CAPS]), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS). It may also be used for other conditions as determined by your doctor.

Rilonacept is an interleukin-1 (IL-1) blocker. It works by blocking the activity of interleukin-1, which reduces inflammation.

Do NOT use Rilonacept if:

• you are allergic to any ingredient in Rilonacept


• you are using an interleukin-1 blocker (eg, anakinra) or tumor necrosis factor (TNF) blockers (eg, etanercept)

Contact your doctor or health care provider right away if any of these apply to you.

Before using Rilonacept:

Some medical conditions may interact with Rilonacept. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have an infection (including an infection that will not go away) or tuberculosis (TB), have had a positive skin test for TB, or have recently been in close contact with someone who has had TB


• if you are at risk for developing an infection, have an open sore or wound, or have a history of infections that keep coming back


• if you have a history of lung or breathing problems (eg, asthma), high cholesterol or triglyceride levels, an immune system problem, HIV, hepatitis, or diabetes


• if you are scheduled for surgery, or you recently received a vaccine or are scheduled for a vaccine


• if you take warfarin

Some MEDICINES MAY INTERACT with Rilonacept. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Interleukin-1 blockers (eg, anakinra), TNF blockers (eg, etanercept), immunosuppressants (eg, cyclosporine), or corticosteroids (eg, prednisone) because the risk of serious infection may be increased


• Live vaccines because their effectiveness may be decreased by Rilonacept

This may not be a complete list of all interactions that may occur. Ask your health care provider if Rilonacept may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Rilonacept:

Use Rilonacept as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• An extra patient leaflet is available with Rilonacept. Talk to your pharmacist if you have questions about this information.


• A health care provider will teach you how to use Rilonacept. Be sure you understand how to use Rilonacept. Follow the procedures you are taught when you use a dose. Contact your health care provider if you have any questions.


• Do not use Rilonacept if it contains particles, is discolored, or if the vial is cracked or damaged.


• Rilonacept may be injected into the abdomen, thigh, or upper arm. Rotate the injection site with each dose. Do not inject Rilonacept into a site that is bruised, red, tender, or hard.


• Use the proper technique taught to you by your doctor. Inject deep under the skin, NOT into muscle.


• Do not use Rilonacept more often than 1 time per week.


• Keep this product, as well as syringes and needles, out of the reach of children and pets. Do not reuse needles, syringes, or other materials. Ask your health care provider how to dispose of these materials after use. Follow all local rules for disposal


• If you miss a dose of Rilonacept, use it as soon as possible, up to the day before your next scheduled dose. Take your next dose at the regularly scheduled time. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Rilonacept.

Important safety information:

• Rilonacept may lower the ability of your body to fight infection. Avoid contact with people who have colds or infections. Tell your doctor if you notice signs of infection like fever, sore throat, rash, or chills. Tell your doctor if you have an open sore or wound.


• Do NOT use more than the recommended dose or use for longer than prescribed without checking with your doctor.


• Tell your doctor or dentist that you take Rilonacept before you receive any medical or dental care, emergency care, or surgery.


• Do not receive a live vaccine (eg, measles, mumps) while you are using Rilonacept. Talk with your doctor before you receive any vaccine.


• You may need to have a TB skin test before you begin using Rilonacept. Contact your doctor with any questions you may have about whether you should receive a TB skin test before using Rilonacept.


• Treatment with medicines that suppress the immune system, including Rilonacept, may increase the risk of developing cancer. Discuss any questions or concerns with your doctor.


• Lab tests, including cholesterol and triglyceride levels, may be performed while you use Rilonacept. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.


• Rilonacept should be used with extreme caution in CHILDREN younger than 12 years old; safety and effectiveness in these children have not been confirmed.


• Rilonacept may affect bone development in CHILDREN and teenagers in some cases. They may need regular growth checks while they use Rilonacept.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Rilonacept while you are pregnant. It is not known if Rilonacept is found in breast milk. If you are or will be breast-feeding while you use Rilonacept, check with your doctor. Discuss any possible risks to your baby.

Possible side effects of Rilonacept:

All medicines may cause side effects, but many people have no, or minor side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Mild pain, swelling, bruising, or redness at the injection site; stuffy nose.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); blood in the stool or stomach pain; fever, chills, cough, or persistent sore throat; flu-like symptoms; increased, decreased, or painful urination; loss of sensation or unusual numbness; unusual lumps or skin growths; vomit that looks like coffee grounds.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Rilonacept side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center ( http://www.aapcc.org), or emergency room immediately.

Proper storage of Rilonacept:

Before mixing, store Rilonacept in the refrigerator between 36 and 46 degrees F (2 and 8 degrees C). Do not freeze. After mixing, Rilonacept may be kept at room temperature and should be used within 3 hours after mixing. Protect Rilonacept from light. Throw away any medicine that is left in the vial after you use your dose. Do not use Rilonacept after the expiration date on the vial. Keep Rilonacept out of the reach of children and away from pets.

General information:

• If you have any questions about Rilonacept, please talk with your doctor, pharmacist, or other health care provider.


• Rilonacept is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Rilonacept. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Rilonacept resources

• Rilonacept Side Effects (in more detail)
• Rilonacept Use in Pregnancy & Breastfeeding
• Rilonacept Drug Interactions
• Rilonacept Support Group
• 1 Review for Rilonacept - Add your own review/rating

• Rilonacept Professional Patient Advice (Wolters Kluwer)


• Rilonacept Monograph (AHFS DI)


• rilonacept Subcutaneous Advanced Consumer (Micromedex) - Includes Dosage Information


• Arcalyst Prescribing Information (FDA)


• Arcalyst Consumer Overview

Compare Rilonacept with other medications

• Cryopyrin-Associated Periodic Syndromes
• Familial Cold Autoinflammatory Syndrome
• Gout
• Muckle Wells Syndrome

Meridol Chlorhexidingluconat

Meridol Chlorhexidingluconat may be available in the countries listed below.

Ingredient matches for Meridol Chlorhexidingluconat

Chlorhexidine

Chlorhexidine digluconate (a derivative of Chlorhexidine) is reported as an ingredient of Meridol Chlorhexidingluconat in the following countries:

• Austria

International Drug Name Search

Mefoxa

Mefoxa may be available in the countries listed below.

Ingredient matches for Mefoxa

Ofloxacin

Ofloxacin is reported as an ingredient of Mefoxa in the following countries:

• Indonesia

International Drug Name Search

Reboxetine

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

N06AX18

CAS registry number (Chemical Abstracts Service)

0098769-81-4

Chemical Formula

C19-H23-N-O3

Molecular Weight

313

Therapeutic Category

Antidepressant: Selective noradrenaline reuptake inhibitor (SNRI)

Chemical Name

(±)-(2R*)-2-[(αR*)-α-(o-Ethoxyphenoxy)benzyl]morpholine

Foreign Names

• Reboxetinum (Latin)
• Reboxetin (German)
• Reboxetine (French)
• Reboxetina (Spanish)

Generic Names

• Reboxetina (OS: DCIT)
• Reboxetine (OS: BAN)
• Reboxetine Mesilate (OS: BANM)
• Reboxetine Mesylate (OS: USAN)
• FCE 20124 (IS: FarmitaliaCarl)
• PNU 155950 E (IS: PharmaciaUpjoh)

Brand Names

• Edronax
  Pfizer, Costa Rica; Pfizer, Finland; Pfizer, Guatemala; Pfizer, Honduras; Pfizer, Croatia (Hrvatska); Pfizer, Ireland; Pfizer, Israel; Pfizer, Latvia; Pfizer, Nicaragua; Pfizer, Oman; Pfizer, Panama; Pfizer, Peru; Pfizer, Poland; Pfizer, Portugal; Pfizer, Sweden; Pfizer, Slovenia; Pfizer, El Salvador; Pfizer, South Africa; Pharmacia, Bulgaria; Pharmacia, Luxembourg



• Narebox
  Zydus Cadila, India



• Prolift
  Pfizer, Chile



• Davedax
  Marvecs, Italy



• Edronax
  Pfizer, Austria; Pfizer, Australia; Pfizer, Belgium; Pfizer, Bahrain; Pfizer, Switzerland; Pfizer, Germany; Pfizer, Denmark; Pfizer, Estonia; Pfizer, United Kingdom; Pfizer, Hungary; Pfizer, Iceland; Pfizer, Italy; Pfizer, Lithuania; Pfizer, Norway; Pfizer, New Zealand; Pfizer, Turkey; Pharmacia, Czech Republic



• Integrex
  Pfizer, Colombia



• Irenor
  Juste, Spain



• Norebox
  Pfizer, Spain



• Prolift
  Pharmacia, Brazil



• Solvex
  Merz, Germany

International Drug Name Search

Glossary

BAN	British Approved Name
BANM	British Approved Name (Modified)
DCIT	Denominazione Comune Italiana
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Glimepiride Mylan

Glimepiride Mylan may be available in the countries listed below.

Ingredient matches for Glimepiride Mylan

Glimepiride

Glimepiride is reported as an ingredient of Glimepiride Mylan in the following countries:

• Belgium


• Italy

International Drug Name Search

Ofloxacino Ges

Ofloxacino Ges may be available in the countries listed below.

Ingredient matches for Ofloxacino Ges

Ofloxacin

Ofloxacin hydrochloride (a derivative of Ofloxacin) is reported as an ingredient of Ofloxacino Ges in the following countries:

• Spain

International Drug Name Search